Bradda Head  Lithium exceeds targets, secures US$3 million royalty and moves closer to production. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EPT Disclosure

1 Feb 2006 11:46

Credit Suisse Securities (Eur) Ltd01 February 2006 FORM 38.5 DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS (Rule 38.5 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION Name of exempt principal trader Credit Suisse Securities (Europe) LtdCompany dealt in Skyepharma PlcClass of relevant security to which the dealings Ordinary Sharesbeing disclosed relate (Note 1) Date of dealing 31 January 2006 2. DEALINGS (Note 2) (a) Purchases and sales Total number of securities Highest price paid (Note Lowest price paid (Note 3)purchased 3) (GBP) (GBP) Total number of securities Highest price received Lowest price received (Notesold (Note 3) (GBP) 3) (GBP) 22,727 0.4450 0.4425 (b) Derivatives transactions (other than options) Product name, e.g. Long/short Number of securities Price per unit (Note 3)CFD (Note 4) (Note 5) (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product Writing, Number of Exercise Type, e.g. Expiry Optionname,e.g. selling, securities price American, date money paid/call purchasing, to which (GBP) European receivedoption varying etc. the option etc. per unit relates (Note 3) (Note 5) (GBP) (ii) Exercising Product name, e.g. Number of Exercise price percall option securities unit (Note 3) 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the persondisclosing and any other person relating to the voting rights of any relevantsecurities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, this should bestated. ..................................................................... None ..................................................................... Date of disclosure 1 February 2006Contact name Jenny LundquistTelephone number 020 7883 4332Name of offeree/offeror with which connected SkyePharma PlcNature of connection (Note 6) Connected party Notes The Notes on Form 38.5 can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
24th Mar 20114:40 pmRNSSecond Price Monitoring Extn
24th Mar 20114:35 pmRNSPrice Monitoring Extension
23rd Mar 20117:00 amRNSFinal Results
10th Mar 201112:25 pmRNSDirector/PDMR Shareholding
7th Mar 20117:00 amRNSDiscontinuation of PULMICORT pMDI production
4th Feb 20115:16 pmRNSDirector/PDMR Shareholding
11th Jan 20112:44 pmRNSDirector/PDMR Shareholding
10th Jan 20114:24 pmRNSChange of Adviser
20th Dec 20104:35 pmRNSPrice Monitoring Extension
9th Dec 20105:00 pmRNSDirector/PDMR Shareholding
3rd Dec 20107:00 amRNSTrading Update
22nd Nov 20103:00 pmRNSResearch Update
8th Nov 20102:55 pmRNSDirector/PDMR Shareholding
21st Oct 20107:00 amRNSInterim Management Statement
21st Oct 20107:00 amRNSInterim Management Statement
12th Oct 20105:53 pmRNSDirector/PDMR Shareholding
4th Oct 20104:40 pmRNSSecond Price Monitoring Extn
4th Oct 20104:35 pmRNSPrice Monitoring Extension
15th Sep 20104:40 pmRNSSecond Price Monitoring Extn
15th Sep 20104:35 pmRNSPrice Monitoring Extension
10th Sep 20103:03 pmRNSDirector/PDMR Shareholding
3rd Sep 20105:24 pmRNSDirector/PDMR Shareholding
20th Aug 20108:16 amRNSRegains US marketing rights to Flutiform
19th Aug 20103:31 pmRNSDirector/PDMR Shareholding
19th Aug 20107:00 amRNSHalf Yearly Report
17th Aug 20107:00 amRNSAppointment of CEO
6th Aug 20102:46 pmRNSDirector/PDMR Shareholding
19th Jul 201010:46 amRNSHolding(s) in Company
16th Jul 201011:29 amRNSDirector/PDMR Shareholding
24th Jun 201011:34 amRNSResearch Update
23rd Jun 20102:47 pmRNSDirector Declaration
15th Jun 20105:15 pmRNSShare Purchase Plan
12th May 201012:06 pmRNSAGM Statement
12th May 20107:00 amRNSInterim Management Statement
11th May 20104:40 pmRNSSecond Price Monitoring Extn
11th May 20104:35 pmRNSPrice Monitoring Extension
11th May 20103:40 pmRNSHolding(s) in Company
7th May 20104:40 pmRNSSecond Price Monitoring Extn
7th May 20104:35 pmRNSPrice Monitoring Extension
5th May 201012:00 pmRNSBoard Change
27th Apr 20103:16 pmRNSAnnual Information Update
14th Apr 20102:27 pmRNSAnnual Report and Accounts
8th Apr 20105:22 pmRNSShare Purchase Plan
25th Mar 20107:00 amRNSFinal Results
1st Mar 201012:46 pmRNSShare Purchase Plan
5th Feb 20102:34 pmRNSFlutiform US NDA update
1st Feb 20105:24 pmRNSShare Purchase Plan
22nd Jan 20101:20 pmRNSHolding(s) in Company
21st Jan 20103:53 pmRNSRegulatory Update
20th Jan 20105:44 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.